• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Dermatology

Pembrolizumab for the treatment of advanced melanoma

byAdarsh ManjunathandMichael Milligan
April 21, 2016
in Dermatology, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. For patients with unresectable melanoma or metastatic melanoma that progressed despite treatment, pembrolizumab treatment resulted in objective response rate of 33%, 12-month progression-free survival rate of 35%, and median overall survival of 23 months.

2. Pembrolizumab administration was associated with a 14% rate of grade 3 or 4 treatment-related adverse events.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Pembrolizumab is a monoclonal antibody that blocks the programmed death-1 pathway, and is used for unresectable melanoma or metastatic melanoma that has progressed after first line treatments. The purpose of this study was to determine the effects of pembrolizumab in terms of antitumor activity and overall survival in patients with advanced melanoma. In an open-label, multi-cohort study across academic medical centers in four countries, data was pooled from 655 enrolled patients and 520 patients from randomized cohorts. Objective responses were reported in 33% of patients with measurable disease and in 45% of patients who were treatment-naïve. Twelve-month progression-free survival rates were 35% in the total population and 52% in treatment-naïve patients. Median overall survival in the total population was 23 months compared to 31 months in the treatment-naïve group. About 14% of patients had 1 treatment-related grade 3 or 4 adverse event, and 9% of patients had a treatment-related serious adverse effect, with no drug-related deaths.

Overall, this study presents response rates and survival rates with pembrolizumab administration. It benefited from having patients enrolled at numerous centers around the world and having a follow-up of 21 months. Further studies are needed to compare pembrolizumab to current standard of care therapies.

Click to read the study in JAMA

RELATED REPORTS

SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure

Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis

Mazdutide significantly reduces weight in adults with overweight or obesity

Relevant Reading: The blockade of immune checkpoints in cancer immunotherapy.

In-Depth [randomized controlled trial]: This open-label, multi-cohort clinical trial looked to determine the tumor response rates and the overall survival among patients with advanced melanoma treated with pembrolizumab. Specifically, data was pooled from 655 enrolled patients and 520 patients from randomized cohorts from academic medical centers in four countries. Patients had to have unresectable melanoma or metastatic melanoma that had progressed after first-line treatments. Objective responses were reported in 33% (95%CI 30-37%) of patients with measurable disease and in 45% (95%CI 36-54%) of patients who were treatment-naïve. Twelve-month progression-free survival rates were 35% (95%CI 31-39%) in the total population and 52% (95%CI 43-60%) in treatment-naïve patients. Median overall survival in the total population was 23 months (95%CI 20-29 months) compared to 31 months (95%CI 24-not reached) in the treatment-naïve group. Approximately 14% of patients had 1 treatment-related grade 3 or 4 adverse event, and 9% of patients had a treatment-related serious adverse effect, with no drug-related deaths.

 

Image: PD

©2016 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Previous Post

Anticholinergic medications linked to worsened cognition, brain metabolism, and atrophy

Next Post

ACE inhibitors alone equally effective, safer versus combination regimen for heart failure patients

RelatedReports

Cardiology

SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure

July 11, 2025
Multiple-electrode switching radiofrequency ablation may successfully treat lung tumors
Pharma

Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis

July 11, 2025
Increasing maternal BMI linked to higher risk of cerebral palsy
Cardiology

Mazdutide significantly reduces weight in adults with overweight or obesity

July 11, 2025
Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn’s disease
Chronic Disease

Oral vancomycin may be effective for pouchitis in inflammatory bowel disease

July 10, 2025
Next Post
ACE inhibitors alone equally effective, safer versus combination regimen for heart failure patients

ACE inhibitors alone equally effective, safer versus combination regimen for heart failure patients

TIAregistry.org provides modern update to etiologies and outcomes in TIA

Screening mammography may result in overdiagnosis of breast cancer

BRCA1 mutation linked to lower AMH levels

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • SGLT2 inhibitors may delay cognitive impairment in elderly patients with heart failure
  • Nerandomilast slows decline in FVC in idiopathic pulmonary fibrosis
  • Mazdutide significantly reduces weight in adults with overweight or obesity
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.